Elvira Argus

Elvira Argus joined the Office of Gene Therapies at FDA/CBER as a biological reviewer in 2022. Elvira conducts review of CMC data for gene therapies, with a focus on ex vivo gene-modified autologous and allogeneic cellular products. Prior to joining the FDA, Elvira worked as a scientist in the pharmaceutical industry to advance IND-enabling and discovery CAR T programs. Elvira received her Bachelor’s in Bioengineering and PhD in Molecular Biology from UCLA.